Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2011

View Archived Issues

Pfizer's final two pivotal trials of tofacitinib in rheumatoid arthritis meet all primary endpoints

Ang-2-VEGF CrossMab simultaneously inhibits tumor growth and angiogenesis

Efficacy of linagliptin in type 2 diabetes is independent of body mass index

GBR-500 slows growth of prostate tumors in vivo

SAR-397769 eye drops show efficacy in model of age-related macular degeneration

New vitamin D receptor ligands disclosed

Topical AMA-0076 reduces intraocular pressure with low systemic exposure

SNP in CDKN2BAS locus correlates with susceptibility to Ph+ acute lymphoblastic leukemia

Bayer claims new hepatocyte growth factor receptor inhibitors

Centocor Ortho Biotech withdraws NDA for Yondelis in recurrent ovarian cancer

GSK patents new antiviral agents for HCV infection

RXi Pharma and UMMS receive grant to develop RNAi therapeutics for ALS

New PI3K-gamma inhibitors disclosed by Vertex Pharma

Jules Stein Eye Institute to be site in phase I/II MA-09-HRPE trials in macular degeneration

Avexxin designs novel cPLA2 inhibitors

Xenon Pharma reports phase IIa data on XEN-402 in postherpetic neuralgia

Apricus Biosciences files MAA in Europe for Vitaros to treat erectile dysfunction

EMA provides Keryx Biopharma with scientific advice on Zerenex in hyperphosphatemia

Boehringer Ingelheim and Lilly receive FDA approval for Tradjenta tablets in type 2 diabetes

AstraZeneca decides not to exercise option to license Targacept's TC-5619

QRxPharma completes enrollment in phase III MoxDuo IR study

Recordati launches pitavastatin in Spain for dyslipidemia

LCT receives approval to conduct phase II trial of Diabecell in Argentina

Ventrus adds third treatment arm to phase III iferanseri study in hemorrhoids

Prometheus obtains U.S. rights for Rencarex for clear cell renal cell carcinoma

Phase II data presented on Androxal in men with hypogonadism and type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...